Serum levels of irisin and nesfatin-1 in multiple sclerosis
ABSTRACT Background: Multiple sclerosis (MS) is an inflammatory and neurodegenerative autoimmune chronic neurological disease. Currently, there are no effective serum biomarkers to verify MS diagnosis, to assess disease prognosis, and evaluate response to MS treatment. Objective: The present stu...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Revinter Publicações
2022-02-01
|
| Series: | Arquivos de Neuro-Psiquiatria |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2022005003204&tlng=en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849695206442532864 |
|---|---|
| author | Mustafa ALTAŞ Ali Ulvi UCA Turan AKDAĞ Faruk Ömer ODABAŞ Osman Serhat TOKGÖZ |
| author_facet | Mustafa ALTAŞ Ali Ulvi UCA Turan AKDAĞ Faruk Ömer ODABAŞ Osman Serhat TOKGÖZ |
| author_sort | Mustafa ALTAŞ |
| collection | DOAJ |
| description | ABSTRACT Background: Multiple sclerosis (MS) is an inflammatory and neurodegenerative autoimmune chronic neurological disease. Currently, there are no effective serum biomarkers to verify MS diagnosis, to assess disease prognosis, and evaluate response to MS treatment. Objective: The present study is a preliminary assessment of irisin and nesfatin-1 serum levels in patients with relapsing- remitting MS (RRMS). Methods: A total of 86 participants, 42 patients with RRMS diagnosis and 44 healthy controls were included in the study. The serum irisin and nesfatin-1 parameters of the patients and control group members were analyzed. Results: Irisin and nesfatin-1 levels of the RRMS patients were significantly lower than the controls (z: -3.82, p<0.001; z: -4.79, p<0.001, respectively) The cut-off level of irisin is 10.390 (ng/mL) (sensitivity: 84.1%, specificity: 71.4%, AUC: 0.800), and the cut-off level of nestatin-1 is 7.155 (ng/mL) (sensitivity: 68.2%, specificity: 64.3%, AUC: 0.739) in the ROC analysis. For these cut-off levels in the case-control groups, the lower irisin and nesfatin-1 levels are the independent variables for MS patients (OR 9.723, 95%CI 2.884-32.785, p<0.001; OR 3.992, 95%CI 1.336-11.928, p<0.001) respectively. Conclusion: The present study revealed lower irisin and nesfatin-1 levels in patients with RRMS. These findings suggest that the decreased levels of irisin and nesfatin-1 peptides may contribute to MS pathogenesis such as inflammation, oxidative stress, and apoptosis in MS, leading to demyelination, axonal damage with neuronal loss, and gliosis. |
| format | Article |
| id | doaj-art-9cc6b9fa661c420d90b9e8501bb0ea05 |
| institution | DOAJ |
| issn | 1678-4227 |
| language | English |
| publishDate | 2022-02-01 |
| publisher | Thieme Revinter Publicações |
| record_format | Article |
| series | Arquivos de Neuro-Psiquiatria |
| spelling | doaj-art-9cc6b9fa661c420d90b9e8501bb0ea052025-08-20T03:19:50ZengThieme Revinter PublicaçõesArquivos de Neuro-Psiquiatria1678-42272022-02-0110.1590/0004-282x-anp-2020-0520Serum levels of irisin and nesfatin-1 in multiple sclerosisMustafa ALTAŞhttps://orcid.org/0000-0003-3011-1062Ali Ulvi UCAhttps://orcid.org/0000-0002-5783-8061Turan AKDAĞhttps://orcid.org/0000-0003-3175-6751Faruk Ömer ODABAŞhttps://orcid.org/0000-0001-9136-9388Osman Serhat TOKGÖZhttps://orcid.org/0000-0002-4919-0285ABSTRACT Background: Multiple sclerosis (MS) is an inflammatory and neurodegenerative autoimmune chronic neurological disease. Currently, there are no effective serum biomarkers to verify MS diagnosis, to assess disease prognosis, and evaluate response to MS treatment. Objective: The present study is a preliminary assessment of irisin and nesfatin-1 serum levels in patients with relapsing- remitting MS (RRMS). Methods: A total of 86 participants, 42 patients with RRMS diagnosis and 44 healthy controls were included in the study. The serum irisin and nesfatin-1 parameters of the patients and control group members were analyzed. Results: Irisin and nesfatin-1 levels of the RRMS patients were significantly lower than the controls (z: -3.82, p<0.001; z: -4.79, p<0.001, respectively) The cut-off level of irisin is 10.390 (ng/mL) (sensitivity: 84.1%, specificity: 71.4%, AUC: 0.800), and the cut-off level of nestatin-1 is 7.155 (ng/mL) (sensitivity: 68.2%, specificity: 64.3%, AUC: 0.739) in the ROC analysis. For these cut-off levels in the case-control groups, the lower irisin and nesfatin-1 levels are the independent variables for MS patients (OR 9.723, 95%CI 2.884-32.785, p<0.001; OR 3.992, 95%CI 1.336-11.928, p<0.001) respectively. Conclusion: The present study revealed lower irisin and nesfatin-1 levels in patients with RRMS. These findings suggest that the decreased levels of irisin and nesfatin-1 peptides may contribute to MS pathogenesis such as inflammation, oxidative stress, and apoptosis in MS, leading to demyelination, axonal damage with neuronal loss, and gliosis.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2022005003204&tlng=enMultiple SclerosisIrisinNesfatin-1InflammationApoptosisOxidative Stress |
| spellingShingle | Mustafa ALTAŞ Ali Ulvi UCA Turan AKDAĞ Faruk Ömer ODABAŞ Osman Serhat TOKGÖZ Serum levels of irisin and nesfatin-1 in multiple sclerosis Arquivos de Neuro-Psiquiatria Multiple Sclerosis Irisin Nesfatin-1 Inflammation Apoptosis Oxidative Stress |
| title | Serum levels of irisin and nesfatin-1 in multiple sclerosis |
| title_full | Serum levels of irisin and nesfatin-1 in multiple sclerosis |
| title_fullStr | Serum levels of irisin and nesfatin-1 in multiple sclerosis |
| title_full_unstemmed | Serum levels of irisin and nesfatin-1 in multiple sclerosis |
| title_short | Serum levels of irisin and nesfatin-1 in multiple sclerosis |
| title_sort | serum levels of irisin and nesfatin 1 in multiple sclerosis |
| topic | Multiple Sclerosis Irisin Nesfatin-1 Inflammation Apoptosis Oxidative Stress |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2022005003204&tlng=en |
| work_keys_str_mv | AT mustafaaltas serumlevelsofirisinandnesfatin1inmultiplesclerosis AT aliulviuca serumlevelsofirisinandnesfatin1inmultiplesclerosis AT turanakdag serumlevelsofirisinandnesfatin1inmultiplesclerosis AT farukomerodabas serumlevelsofirisinandnesfatin1inmultiplesclerosis AT osmanserhattokgoz serumlevelsofirisinandnesfatin1inmultiplesclerosis |